Ascentage Pharma Group International (AAPG) financial statements

Healthcare · Biotechnology · Market cap $1.3B

Ascentage Pharma Group International reported revenue of 981M CNY in fiscal 2024, up 116.2% a year over 2 years.

Net income was -405M CNY.

Free cash flow was -136M CNY.

The diluted share count rose 15% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (CNY).

Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

<iframe src="https://investingly.io/embed/AAPG/financials" width="100%" height="330" style="border:0;max-width:680px" title="Ascentage Pharma Group International revenue and free cash flow" loading="lazy"></iframe>
<p style="font-size:13px">Source: <a href="https://investingly.io/stocks/AAPG/financials">Ascentage Pharma Group International financials</a> on Investingly</p>

Income statement

Fiscal years, in CNY, from Ascentage Pharma Group International's 10-K filings with the SEC.

Fiscal year	2022	2023	2024
Revenue	210M CNY	222M CNY	981M CNY
Cost of revenue	22M CNY	31M CNY	29M CNY
Gross profit	188M CNY	191M CNY	952M CNY
Research and development	743M CNY	707M CNY	947M CNY
Selling, general and admin	328M CNY	376M CNY	383M CNY
Interest expense	53M CNY	96M CNY	64M CNY
Pre-tax income	-887M CNY	-933M CNY	-395M CNY
Income tax	-4M CNY	-7M CNY	10M CNY
Net income	-883M CNY	-926M CNY	-405M CNY
EPS (diluted)	-3.35 CNY	-3.28 CNY	-1.34 CNY
Diluted shares	264M	282M	302M
Gross margin	89.5%	86.2%	97.0%
Net margin	-421.0%	-417.0%	-41.3%

Balance sheet

Fiscal years, in CNY, from Ascentage Pharma Group International's 10-K filings with the SEC.

Fiscal year	2022	2023	2024
Cash and short-term investments	1.3B CNY	1.0B CNY	893M CNY
Receivables	—	146M CNY	83M CNY
Inventory	—	16M CNY	7M CNY
Total current assets	—	1.3B CNY	1.5B CNY
Property, plant and equipment	—	906M CNY	849M CNY
Goodwill	—	25M CNY	25M CNY
Total current liabilities	—	934M CNY	1.2B CNY
Long-term debt	—	1.2B CNY	889M CNY
Total liabilities	—	2.4B CNY	2.3B CNY
Shareholders' equity	409M CNY	60M CNY	264M CNY
Net debt	-1.3B CNY	758M CNY	775M CNY

Cash flow

Fiscal years, in CNY, from Ascentage Pharma Group International's 10-K filings with the SEC.

Fiscal year	2022	2023	2024
Operating cash flow	-654M CNY	-726M CNY	-111M CNY
Capital spending	237M CNY	57M CNY	24M CNY
Free cash flow	-891M CNY	-783M CNY	-136M CNY
Stock-based compensation	22M CNY	32M CNY	21M CNY
Share buybacks (net)	-27M CNY	-6M CNY	—
Net borrowing	709M CNY	-3M CNY	-137M CNY
Free cash flow margin	-424.8%	-352.7%	-13.8%

Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AAPG.

Open AAPG in Investingly

Questions

What was Ascentage Pharma Group International's revenue in 2024?

981M CNY in fiscal 2024, from its 10-K filing.

How much free cash flow does Ascentage Pharma Group International generate?

-136M CNY in fiscal 2024 (operating cash flow minus capital spending).

From Ascentage Pharma Group International's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.